Insight II and Catalyst Now Available on Linux
SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ — Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP) today announced the Linux releases of Insight II(R) and Catalyst(R), its leading software suites for macromolecular modeling and rational drug design. Insight II and Catalyst software now runs on Linux workstations, giving users a significantly
increased choice of high performance hardware and improved price/performance within a new, affordable desktop alternative. Completed in collaboration with IBM, Accelrys’ premier life science partner, Insight II and Catalystare now available as both clients and servers with certification on the latest IBM IntelliStation(R) workstations running Red Hat Linux.
The move to Linux is in direct response to customer interest in the low cost and high performance value offered by Linux based systems. Previously available on Linux based servers, researchers will now benefit from the stability, speed, and graphical capabilities of Catalyst and Insight II running on Linux clients as well. With a client port to Linux Red Hat WS2.1, Catalyst is now available as a one-box solution on Linux. Insight II offers a flexible 3D graphical environment that integrates powerful tools for the modeling, simulation, analysis, and visualization of macromolecular systems.
For compute-intensive calculations both Catalyst and Insight II users can now choose between Linux, AIX(R) or IRIX, for example, selecting IBM eServer(TM) systems running either Linux or IBM AIX.
“Accelrys is committed to supporting researchers on the platforms they find most conducive to their work. In embracing Linux solutions, we are delivering great science on one of the most flexible and cost effective platforms available today,” said Mark Emkjer, president of Accelrys. “Our aim to is to help the scientists we serve to achieve their research goals, and we are pleased by the response we received from our customers on these new versions.”
About Catalyst and Insight II
The Catalyst software suite provides an integrated environment for 3D information management and querying tasks that are extremely valuable in drug discovery research. This integrated environment allows for seamless access to complementary capabilities such as pharmacophore-based alignment of molecules, shape-based 3D searching, and automated generation of pharmacophore hypotheses based on SAR data. The Insight II software suite provides a flexible 3D graphical environment, which integrates powerful tools for the modeling, simulation, analysis, and visualization of macromolecular systems. This integrated approach rapidly provides information that can further enable the drug discovery process.
About Accelrys
Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys technology and services are designed to meet the needs of today’s leading research organizations. The company is headquartered in San Diego, California, USA. Accelrys is currently a subsidiary of Pharmacopeia, Inc.
(Nasdaq: PCOP). More information athttp://www.accelrys.com/.
When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Accelrys
Jim Rivas
(858) 799-5393
jrivas@accelrys.com
